CFS
MCID: CHR066
MIFTS: 64

Chronic Fatigue Syndrome (CFS) malady

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Chronic Fatigue Syndrome

Aliases & Descriptions for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome 12 50 52 41 3 14 69
Cfs 12 3 14
Myalgic Encephalomyelitis 12 50
Chronic Fatigue Immune Dysfunction Syndrome 50
Systemic Exertion Intolerance Disease 50
Postviral Fatigue Syndrome 12
Fatigue Syndrome, Chronic 42
Myalgic Encephalitis 12

Classifications:



Summaries for Chronic Fatigue Syndrome

MedlinePlus : 41 chronic fatigue syndrome (cfs) is a disorder that causes extreme fatigue. this fatigue is not the kind of tired feeling that goes away after you rest. instead, it lasts a long time and limits your ability to do ordinary daily activities. the main symptom of cfs is severe fatigue that lasts for 6 months or more. you also have at least four of these other symptoms: feeling unwell for more than 24 hours after physical activity muscle pain memory problems headaches pain in multiple joints sleep problems sore throat tender lymph nodes cfs is hard to diagnose. there are no tests for it, and other illnesses can cause similar symptoms. your doctor has to rule out other diseases before making a diagnosis of cfs. no one knows what causes cfs. it is most common in women in their 40s and 50s, but anyone can have it. it can last for years. there is no cure for cfs, so the goal of treatment is to improve symptoms. cfs affects people in different ways. you should work with your doctors to create a treatment program that best meets your own needs. it may include therapies to manage your symptoms, such as medicines to treat pain, sleep disorders, and other problems. it may also include coping techniques, and ways of managing your daily activities. centers for disease control and prevention

MalaCards based summary : Chronic Fatigue Syndrome, also known as cfs, is related to hypoglycemia and hepatitis, and has symptoms including back pain, fatigue and fever. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways/superpathways are TGF-Beta Pathway and Akt Signaling. The drugs Dopamine and Sodium oxybate have been mentioned in the context of this disorder. Affiliated tissues include lymph node, testes and prostate, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and behavior/neurological

Disease Ontology : 12 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

NIH Rare Diseases : 50 chronic fatigue syndrome, also known as systemic exertion intolerance disease, is a condition that causes extreme, long-lasting fatigue which can limit the ability to participate in ordinary, daily activities. it generally occurs in young adults (20 to 40 years of age) and is twice as common in women. the main symptom is disabling fatigue that does not improve with rest. other signs and symptoms may include muscle pain, joint pain, concentration and memory problems, headaches, sleep problems, fever, sore throat, and/or tender lymph nodes. the exact cause is not known. there is still no cure or effective treatment for this condition but there are several clinical trials. there is controversy and debate in the medical literature about the relationship between myalgic encephalomyelitis and chronic fatigue syndrome and there is no consensus on nomenclature or classification for these disorders. different countries, organizations, and researchers continue to use different names to describe these conditions. last updated: 10/18/2016

CDC : 3 Chronic fatigue syndrome, or CFS, is a debilitating and complex disorder characterized by profound fatigue that is not improved by bed rest and that may be worsened by physical or mental activity. Symptoms affect several body systems and may include weakness, muscle pain, impaired memory and/or mental concentration, and insomnia, which can result in reduced participation in daily activities.

Wikipedia : 71 Chronic fatigue syndrome (CFS), also referred to as myalgic encephalomyelitis (ME), is a medical... more...

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
id Related Disease Score Top Affiliating Genes
1 hypoglycemia 29.5 CRH POMC SLC6A4
2 hepatitis 29.5 IL10 IL2 IL6 TNF
3 personality disorder 29.5 COMT CRH HTR1A HTR2A MAOA POMC
4 rheumatoid arthritis 29.1 CXCL8 IL10 IL1B IL2 IL6 TGFB1
5 irritable bowel syndrome 11.0
6 chronic pain 11.0
7 corticosteroid-binding globulin deficiency 10.7
8 persian gulf syndrome 10.7
9 nonparalytic poliomyelitis 10.3 CRH NR3C1 POMC
10 merkel cell carcinoma 10.3 CRH NR3C1 POMC
11 esophagus squamous cell papilloma 10.3 CRH NR3C1 POMC
12 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations 10.3 CRH NR3C1 POMC
13 conjunctival pigmentation 10.3 CRH MAOA SLC6A4
14 dacryoadenitis 10.3 CRH IGF1 POMC
15 femur bifid with monodactylous ectrodactyly 10.3 CRH IGF1 POMC
16 vaginal adenoma 10.3 IGF1 POMC
17 clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly 10.3 IL10 IL2 NR3C1
18 traumatic glaucoma 10.3 CRH IGF1 POMC
19 maturity-onset diabetes of the young 10.3 COMT IL10
20 colorectal adenocarcinoma 10.3 COMT MAOA SLC6A4
21 glucosephosphate dehydrogenase deficiency 10.3 IL1B IL6 POMC
22 strongyloidiasis 10.3 COMT MAOA SLC6A4
23 apperceptive agnosia 10.3 COMT HTR1A SLC6A4
24 laryngotracheoesophageal cleft type 2 10.3 IL1B IL2 IL6
25 adult brainstem astrocytoma 10.2 HTR1A MAOA SLC6A4
26 immune system organ benign neoplasm 10.2 CRH IGF1 POMC
27 kidney pelvis papillary carcinoma 10.2 HTR1A MAOA SLC6A4
28 pyridoxal 5'-phosphate-dependent epilepsy 10.2 IL10 TNF
29 luxation of globe 10.2 HTR1A IL6 SLC6A4
30 urethra clear cell adenocarcinoma 10.2 CRH IGF1 POMC
31 tinea pedis 10.2 HTR1A MAOA SLC6A4
32 intussusception 10.2 IL1B TNF
33 refractory celiac disease 10.2 IL10 TGFB1
34 steatitis 10.2 IL2 TNF
35 nephronophthisis 13 10.2 COMT HTR2A SLC6A4
36 leukemia 10.2
37 neurogenic bladder 10.2 HTR2A MAOA SLC6A4
38 carotid stenosis 10.2 COMT MAOA POMC SLC6A4
39 pyromania 10.2 HTR2A MAOA SLC6A4
40 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.2 IL6 TNF
41 stickler syndrome, type v 10.2 IL1B IL2 IL6
42 causalgia 10.2 IL10 IL2 IL6
43 dry eye syndrome 10.2 HTR1A HTR2A SLC6A4
44 transient tic disorder 10.2 IL10 IL6 TNF
45 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.2 IL10 IL2 TNF
46 waardenburg's syndrome 10.2 HTR1A HTR2A SLC6A4
47 tubular renal disease-cardiomyopathy syndrome 10.2 IL10 TNF
48 phlyctenulosis 10.2 IL10 IL6 TNF
49 conduct disorder 10.2 IL10 IL6 TNF
50 pancreatic signet ring cell adenocarcinoma 10.2 IL10 IL6 TNF

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:



Diseases related to Chronic Fatigue Syndrome

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:


back pain, fatigue, fever, (non-specific) malaise and fatigue, muscle cramp, muscle rigidity, muscle spasticity, pruritus, sciatica, muscle weakness, myalgia, other malaise and fatigue

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 TGFB1 TNF CXCL8 EIF2AK2 IL10 IL1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 TGFB1 TNF CXCL8 EIF2AK2 IL10 IL1B
3 Decreased viability with paclitaxel GR00179-A-1 9.35 IGF1 IL10 TGFB1
4 Decreased viability with paclitaxel GR00179-A-2 9.35 IGF1
5 Decreased viability with paclitaxel GR00179-A-3 9.35 TGFB1

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.42 COMT CRH HTR1A HTR2A IL10 IL2
2 homeostasis/metabolism MP:0005376 10.39 IL1B IL2 IL6 MAOA NR3C1 POMC
3 cardiovascular system MP:0005385 10.38 COMT HTR1A IGF1 IL10 IL1B IL2
4 endocrine/exocrine gland MP:0005379 10.36 TNF COMT CRH HTR2A IGF1 IL10
5 cellular MP:0005384 10.34 CRH EIF2AK2 IGF1 IL10 IL2 IL6
6 hematopoietic system MP:0005397 10.34 COMT CRH EIF2AK2 IGF1 IL10 IL1B
7 growth/size/body region MP:0005378 10.31 CRH IGF1 IL10 IL2 IL6 NR3C1
8 immune system MP:0005387 10.31 IL1B IL2 IL6 NR3C1 POMC RNASEL
9 mortality/aging MP:0010768 10.28 EIF2AK2 HTR1A IGF1 IL10 IL1B IL2
10 integument MP:0010771 10.18 CRH IGF1 IL10 IL1B IL6 NR3C1
11 nervous system MP:0003631 10.17 COMT CRH HTR1A IGF1 IL10 IL1B
12 adipose tissue MP:0005375 10.13 TGFB1 TNF CRH IGF1 IL6 NR3C1
13 liver/biliary system MP:0005370 10.06 CRH IL10 IL2 IL6 NR3C1 POMC
14 muscle MP:0005369 10.06 IL10 IL6 NR3C1 SLC6A4 SUN2 TGFB1
15 neoplasm MP:0002006 10.02 IL10 IL1B IL2 IL6 POMC TGFB1
16 reproductive system MP:0005389 9.81 COMT IGF1 IL10 IL2 IL6 NR3C1
17 renal/urinary system MP:0005367 9.8 TGFB1 COMT CRH IGF1 IL6 NR3C1
18 respiratory system MP:0005388 9.61 COMT CRH IGF1 IL10 IL2 IL6
19 skeleton MP:0005390 9.32 PDCD2 TGFB1 TNF CRH HTR2A IGF1

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
2
Sodium oxybate Approved Phase 4 502-85-2 5360545
3
Dinoprostone Approved Phase 4 363-24-6 5280360
4
Zinc Approved Phase 4 7440-66-6 32051 23994
5
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
6
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
7
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
8
Milnacipran Approved Phase 4,Phase 3 92623-85-3 65833
9
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
10
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 73-31-4 896
11
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
12 tannic acid Approved, Nutraceutical Phase 4,Phase 3
13 vitamin d Phase 4,Phase 2
14 Sildenafil Citrate Phase 4 171599-83-0
15
Serotonin Phase 4,Phase 2,Phase 3 50-67-9 5202
16 Adjuvants, Anesthesia Phase 4,Phase 1
17 Serotonin Agents Phase 4,Phase 3,Phase 2
18 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
19 Serotonin Uptake Inhibitors Phase 4,Phase 3
20 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
21 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
22 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
23 Anesthetics Phase 4,Phase 3,Phase 1
24 Anesthetics, General Phase 4
25 Anesthetics, Intravenous Phase 4
26 Dopamine Agents Phase 4,Phase 2,Phase 3
27 Vasodilator Agents Phase 4,Phase 1
28 Dopamine Uptake Inhibitors Phase 4,Phase 2
29 Ergocalciferols Phase 4
30 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
31 Phosphodiesterase 5 Inhibitors Phase 4
32 Phosphodiesterase Inhibitors Phase 4
33 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Antidepressive Agents Phase 4,Phase 2,Phase 3
36 Psychotropic Drugs Phase 4,Phase 2,Phase 3
37 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
38 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
39 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
40 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1
41 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
42 Central Nervous System Stimulants Phase 4,Phase 2
43 Epoetin alfa Phase 4,Phase 2 113427-24-0
44 interferons Phase 4,Phase 3
45 Hematinics Phase 4,Phase 3,Phase 2
46 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Antimalarials Phase 4
48 Liver Extracts Phase 4
49 Antimetabolites Phase 4,Phase 3
50 Lisdexamfetamine Dimesylate Phase 4

Interventional clinical trials:

(show top 50) (show all 239)
id Name Status NCT ID Phase
1 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4
2 Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS Unknown status NCT00598585 Phase 4
3 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
4 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4
5 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4
6 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome Completed NCT01071044 Phase 4
7 Giardia Induced Fatigue and Functional Gastrointestinal Diseases Completed NCT00860236 Phase 4
8 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Completed NCT01318356 Phase 4
9 Exercise Effect on Aerobic Capacity and QOL in Heart Failure Completed NCT00013221 Phase 4
10 A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia Completed NCT01173055 Phase 4
11 The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia Completed NCT01234675 Phase 4
12 Oral Melatonin Plus Zinc Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) Recruiting NCT03000777 Phase 4
13 CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS Active, not recruiting NCT02402218 Phase 4
14 Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome Terminated NCT00498485 Phase 4
15 Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin Terminated NCT00194857 Phase 4
16 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4
17 Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS. Unknown status NCT01907711 Phase 2, Phase 3
18 Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise Unknown status NCT01689467 Phase 2, Phase 3
19 Immune-Pineal Axis Function in Fibromyalgia Unknown status NCT02041455 Phase 2, Phase 3
20 A Randomized Trial of Oral Iron Therapy in Fibromyalgia Unknown status NCT01820052 Phase 3
21 Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome Completed NCT00375973 Phase 2, Phase 3
22 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3
23 Drug Intervention in Chronic Fatigue Syndrome Completed NCT00848692 Phase 2, Phase 3
24 The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome Completed NCT00215800 Phase 3
25 Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients Completed NCT01742013 Phase 3
26 Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. Completed NCT02063126 Phase 2, Phase 3
27 Exercise and Behavioral Therapy Trial (EBT). Completed NCT00007748 Phase 3
28 Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ Completed NCT00552682 Phase 3
29 Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis Completed NCT01149525 Phase 3
30 Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin Completed NCT00196664 Phase 3
31 Online Acceptance-based Behavioural Treatment for Fibromyalgia Completed NCT01642810 Phase 3
32 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
33 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
34 Study and Treatment of Post Lyme Disease (STOP-LD) Completed NCT00000937 Phase 3
35 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
36 Fibromyalgia Treatment Trial With Gabapentin and Osteopathic Manipulative Medicine Completed NCT01107574 Phase 3
37 Tailored Treatments of Fibromyalgia Completed NCT00000422 Phase 2, Phase 3
38 Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia Completed NCT00321451 Phase 2, Phase 3
39 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
40 Study of Milnacipran for the Treatment of Fibromyalgia Completed NCT00098124 Phase 3
41 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00316914 Phase 3
42 A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) Completed NCT02158936 Phase 3
43 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
44 Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome Recruiting NCT02067910 Phase 3
45 Combined Western and Traditional Chinese Medicine Daycare for CKD Patients Recruiting NCT02545036 Phase 3
46 Probiotic (Visbiome) for Gulf War Illness Recruiting NCT03078530 Phase 2, Phase 3
47 Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT02949128 Phase 3
48 Evaluation of Spa Therapy in the Treatment of Fibromyalgia Recruiting NCT02265029 Phase 3
49 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) Recruiting NCT01376778 Phase 3
50 ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT02946463 Phase 3

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

Anatomical Context for Chronic Fatigue Syndrome

MalaCards organs/tissues related to Chronic Fatigue Syndrome:

39
Lymph Node, Testes, Prostate, Brain, Pituitary, Heart, B Cells

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

(show top 50) (show all 786)
id Title Authors Year
1
Children's experiences of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review and meta-ethnography of qualitative studies. ( 28087544 )
2017
2
Fatigue and psychosocial variables in autoimmune rheumatic disease and chronic fatigue syndrome: A cross-sectional comparison. ( 27998507 )
2017
3
Treatment and management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: all roads lead to Rome. ( 28052319 )
2017
4
Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. ( 27727448 )
2017
5
Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. ( 28059425 )
2017
6
Poor sleep quality is associated with greater circulating pro-inflammatory cytokines and severity and frequency of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) symptoms in women. ( 28038892 )
2017
7
Exploring the potential role of the advanced nurse practitioner within a care path for patients with chronic fatigue syndrome. ( 28000331 )
2016
8
Emotional Suppression in Chronic Fatigue Syndrome: Experimental Study. ( 27183308 )
2016
9
Obesity in adolescents with chronic fatigue syndrome: an observational study. ( 27655658 )
2016
10
Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures. ( 27165859 )
2016
11
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis. ( 28066845 )
2016
12
Correction: Therapist Effects and the Impact of Early Therapeutic Alliance on Symptomatic Outcome in Chronic Fatigue Syndrome. ( 27191956 )
2016
13
The Relationship between Age and Illness Duration in Chronic Fatigue Syndrome. ( 27110826 )
2016
14
Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome. ( 26615570 )
2016
15
Adiponectin potentially contributes to the anti-depressive effects of Baduanjin Qigong exercise in women with chronic fatigue syndrome-like illness. ( 27938498 )
2016
16
Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome. ( 27536947 )
2016
17
Metabolic mechanism of a polysaccharide from Schisandra chinensis to relieve chronic fatigue syndrome. ( 27545408 )
2016
18
Mortality in Patients with Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. ( 28070451 )
2016
19
Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study. ( 27123773 )
2016
20
A qualitative investigation of eating difficulties in adolescents with chronic fatigue syndrome/myalgic encephalomyelitis. ( 27215228 )
2016
21
Emotional conflict processing in adolescent chronic fatigue syndrome: A pilot study using functional magnetic resonance imaging. ( 27647312 )
2016
22
Association of biomarkers with health-related quality of life and history of stressors in myalgic encephalomyelitis/chronic fatigue syndrome patients. ( 27580693 )
2016
23
Cognitive behavioural therapy in the treatment of chronic fatigue syndrome: A narrative review on efficacy and informed consent. ( 27634687 )
2016
24
Reply to: Myalgic Encephalomyelitis, chronic fatigue syndrome or systemic exercise intolerance disease: What's in a name? ( 27931912 )
2016
25
ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56(dim)CD16(+) and CD56(bright)CD16(dim/-) natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. ( 27098723 )
2016
26
Cow's Milk Protein Intolerance in Adolescents and Young Adults with Chronic Fatigue Syndrome. ( 27177188 )
2016
27
Mitochondrial dysfunction in a family with psychosis and chronic fatigue syndrome. ( 27989882 )
2016
28
A UK based review of recommendations regarding the management of chronic fatigue syndrome. ( 27521650 )
2016
29
Genetic evaluation of AMPD1, CPT2, and PGYM metabolic enzymes in patients with chronic fatigue syndrome. ( 27525900 )
2016
30
Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. ( 28018972 )
2016
31
Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. ( 27099524 )
2016
32
Comorbidities treated in primary care in children with chronic fatigue syndrome / myalgic encephalomyelitis: A nationwide registry linkage study from Norway. ( 27590471 )
2016
33
Chronic fatigue syndrome in women assessed with combined cardiac magnetic resonance imaging. ( 27561279 )
2016
34
Group Cognitive Behaviour Therapy for Chronic Fatigue Syndrome. ( 27513528 )
2016
35
Autonomic correlations with MRI are abnormal in the brainstem vasomotor centre in Chronic Fatigue Syndrome. ( 27114901 )
2016
36
Enhanced psychological flexibility and improved quality of life in chronic fatigue syndrome/myalgic encephalomyelitis. ( 27521652 )
2016
37
The utility of patient-reported outcome measures among patients with myalgic encephalomyelitis/chronic fatigue syndrome. ( 27600520 )
2016
38
Assessing the reliability of the five minute speech sample against the Camberwell family interview in a chronic fatigue syndrome sample. ( 27095328 )
2016
39
High-frequency rTMS for the Treatment of Chronic Fatigue Syndrome: A Case Series. ( 27904120 )
2016
40
Metabolic features of chronic fatigue syndrome. ( 27573827 )
2016
41
Ubiquinol-10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome. ( 27125909 )
2016
42
Factors determining fatigue in the chronic fatigue syndrome: a path analysis. ( 27143625 )
2016
43
For chronic fatigue syndrome, a 'shifting tide' at NIH. ( 27846583 )
2016
44
The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimmune processes with an emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome. ( 27634186 )
2016
45
Review: Exercise therapy reduces fatigue in chronic fatigue syndrome. ( 27182921 )
2016
46
Epistemic injustice in healthcare encounters: evidence from chronic fatigue syndrome. ( 27920164 )
2016
47
The psychological impact of dependency in adults with chronic fatigue syndrome/myalgic encephalomyelitis: A qualitative exploration. ( 27098385 )
2016
48
Association of mitochondrial DNA variants with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) symptoms. ( 27998272 )
2016
49
Supplements for Chronic Fatigue Syndrome? ( 27630530 )
2016
50
Fatigue Exacerbation by Interval or Continuous Exercise in Chronic Fatigue Syndrome. ( 27183124 )
2016

Variations for Chronic Fatigue Syndrome

Expression for Chronic Fatigue Syndrome

Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 CXCL8 EIF2AK2 IGF1 IL10 IL1B IL2
2
Show member pathways
13.47 CXCL8 IGF1 IL10 IL1B IL2 IL6
3
Show member pathways
13.4 CXCL8 EIF2AK2 IL10 IL1B IL2 IL6
4
Show member pathways
13.36 CXCL8 IGF1 IL10 IL1B IL2 IL6
5
Show member pathways
13 CXCL8 IL10 IL1B IL2 IL6 TGFB1
6
Show member pathways
12.94 CXCL8 IL10 IL1B IL2 IL6 TGFB1
7
Show member pathways
12.89 CXCL8 EIF2AK2 IL1B IL2 IL6 RNASEL
8
Show member pathways
12.78 EIF2AK2 IGF1 IL1B IL2 IL6 TGFB1
9
Show member pathways
12.68 IL10 IL1B IL2 IL6 TGFB1 TNF
10
Show member pathways
12.68 EIF2AK2 IL10 IL1B IL2 IL6 TNF
11 12.6 IL10 IL1B IL2 RNASEL TNF
12
Show member pathways
12.53 IL10 IL1B IL2 IL6 TGFB1 TNF
13
Show member pathways
12.37 IL1B IL2 IL6 TNF
14
Show member pathways
12.37 CXCL8 IL1B IL6 TNF
15
Show member pathways
12.32 CXCL8 IL1B IL6 TNF
16 12.32 IL10 IL1B IL6 TGFB1 TNF
17
Show member pathways
12.3 IL10 IL1B TGFB1 TNF
18
Show member pathways
12.26 IGF1 IL6 TGFB1 TNF
19
Show member pathways
12.23 CXCL8 IL1B IL6 TNF
20 12.16 IGF1 IL6 NR3C1 TGFB1 TNF
21
Show member pathways
12.15 IGF1 IL10 IL6 TGFB1
22 12.12 CXCL8 EIF2AK2 RNASEL TNF
23 12.09 CXCL8 IL1B IL2 IL6 TGFB1 TNF
24
Show member pathways
12.08 CXCL8 IL10 IL1B IL2 IL6 RNASEL
25 12.07 IL10 IL2 IL6 TNF
26 12.05 HTR1A HTR2A MAOA SLC6A4
27 12 CXCL8 IL1B IL6 TGFB1 TNF
28
Show member pathways
12 IL10 IL1B IL2 IL6 TGFB1 TNF
29 11.98 CXCL8 IGF1 IL1B IL6 RNASEL TGFB1
30 11.96 CRH CXCL8 IL2 POMC TGFB1
31 11.94 CXCL8 IL1B IL6 TGFB1 TNF
32 11.92 CXCL8 IL10 IL1B IL6 TGFB1 TNF
33 11.89 IL10 IL1B IL2 TNF
34 11.88 CXCL8 IL2 IL6 NR3C1 POMC
35 11.84 CXCL8 IL10 IL1B IL6 TNF
36 11.82 IL10 IL6 TGFB1 TNF
37
Show member pathways
11.79 CXCL8 IL2 TNF
38 11.79 IL10 IL1B IL2 IL6 TGFB1 TNF
39 11.73 IL10 IL2 IL6
40 11.7 CXCL8 IL1B IL6 TNF
41 11.68 CXCL8 IGF1 IL1B IL6 TGFB1 TNF
42
Show member pathways
11.64 CXCL8 IL1B IL2 IL6 NR3C1 TNF
43 11.63 IL1B IL2 TGFB1 TNF
44 11.61 CXCL8 IL6 TGFB1
45 11.61 CXCL8 IL10 IL1B IL6 TNF
46 11.61 CXCL8 IL10 IL1B IL6 MAOA POMC
47 11.6 IL2 IL6 TNF
48 11.57 IGF1 IL6 TGFB1
49
Show member pathways
11.57 IL1B MAOA SLC6A4 TNF
50 11.56 IGF1 IL1B IL6 NR3C1 TNF

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CRH CXCL8 IGF1 IL10 IL1B IL2
2 extracellular space GO:0005615 9.32 CRH CXCL8 IGF1 IL10 IL1B IL2

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.99 COMT IL10 IL1B IL6
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 HTR2A IL6 TGFB1 TNF
3 aging GO:0007568 9.97 HTR2A IL10 IL6 TGFB1
4 positive regulation of gene expression GO:0010628 9.95 CRH IL1B IL6 SLC6A4 TGFB1 TNF
5 positive regulation of cell proliferation GO:0008284 9.95 CRH HTR1A HTR2A IGF1 IL2 IL6
6 cellular response to lipopolysaccharide GO:0071222 9.91 CXCL8 IL10 IL6 TNF
7 cellular response to organic cyclic compound GO:0071407 9.9 IL1B TGFB1 TNF
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.89 IL6 TGFB1 TNF
9 response to glucocorticoid GO:0051384 9.88 IL10 IL6 TNF
10 positive regulation of epithelial cell proliferation GO:0050679 9.88 IGF1 IL6 TGFB1
11 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.88 IL10 IL1B IL6 TNF
12 positive regulation of T cell proliferation GO:0042102 9.87 IL1B IL2 IL6
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 IGF1 IL6 TNF
14 positive regulation of MAP kinase activity GO:0043406 9.86 HTR2A TGFB1 TNF
15 positive regulation of protein phosphorylation GO:0001934 9.85 CRH IL1B IL2 TGFB1 TNF
16 response to organic substance GO:0010033 9.84 IL10 SLC6A4 TGFB1 TNF
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IGF1 IL2 IL6
18 positive regulation of interferon-gamma production GO:0032729 9.82 IL1B IL2 TNF
19 negative regulation of fat cell differentiation GO:0045599 9.82 IL6 TGFB1 TNF
20 positive regulation of interleukin-6 production GO:0032755 9.81 IL1B IL6 TNF
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.81 IL1B IL6 TNF
22 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 HTR2A IGF1 IL6 TGFB1
23 negative regulation of viral genome replication GO:0045071 9.8 EIF2AK2 RNASEL TNF
24 inflammatory response GO:0006954 9.8 CRH CXCL8 IL10 IL1B IL6 TGFB1
25 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 IL1B TGFB1 TNF
26 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.77 EIF2AK2 IL1B IL6 TGFB1 TNF
27 negative regulation of mitotic cell cycle GO:0045930 9.74 IL10 TGFB1 TNF
28 behavior GO:0007610 9.72 HTR1A HTR2A
29 neurotransmitter catabolic process GO:0042135 9.72 COMT MAOA
30 positive regulation of regulatory T cell differentiation GO:0045591 9.71 IL2 TGFB1
31 positive regulation of chemokine biosynthetic process GO:0045080 9.71 IL1B TNF
32 catecholamine metabolic process GO:0006584 9.71 COMT MAOA
33 negative regulation of lipid storage GO:0010888 9.71 IL6 TNF
34 regulation of behavior GO:0050795 9.7 HTR1A HTR2A
35 dopamine catabolic process GO:0042420 9.7 COMT MAOA
36 endothelial cell apoptotic process GO:0072577 9.69 IL10 TNF
37 serotonin receptor signaling pathway GO:0007210 9.69 HTR1A HTR2A
38 regulation of establishment of endothelial barrier GO:1903140 9.68 IL1B TNF
39 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 IL10 TNF
40 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.67 IL6 TNF
41 positive regulation of chemokine production GO:0032722 9.67 EIF2AK2 IL6 TNF
42 regulation of hormone secretion GO:0046883 9.66 HTR1A HTR2A
43 positive regulation of fever generation GO:0031622 9.65 IL1B TNF
44 sequestering of triglyceride GO:0030730 9.62 IL1B TNF
45 positive regulation of mononuclear cell migration GO:0071677 9.62 TGFB1 TNF
46 cellular response to dexamethasone stimulus GO:0071549 9.62 CRH IL6 NR3C1 TGFB1
47 receptor biosynthetic process GO:0032800 9.61 IL10 TNF
48 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL10 IL1B TNF
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.6 IL1B TNF
50 regulation of hematopoietic progenitor cell differentiation GO:1901532 9.56 EIF2AK2 PDCD2

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IGF1 IL10 IL2 IL6 TGFB1
2 cytokine activity GO:0005125 9.17 CXCL8 IL10 IL1B IL2 IL6 TGFB1
3 serotonin binding GO:0051378 9.16 HTR1A HTR2A

Sources for Chronic Fatigue Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....